Cytovation Secures $6M Funding to Advance CY-101 Cancer Therapy into Phase II Trials
• Norwegian biotech Cytovation ASA has raised an additional $6 million from existing investors, bringing their total capital to $34 million to support Phase II trials of their cancer vaccine CY-101.
• CY-101 is a novel membranolytic inhibitor that forms pores in cancer cells and inhibits the Wnt/β-catenin pathway, showing promising preclinical results in adrenocortical carcinoma, colorectal cancer, and melanoma.
• The upcoming multi-center Phase II trial, conducted in partnership with Cancer Research UK, will focus on adrenocortical carcinoma patients with clinical readouts expected in 2026.
CY-101 Enters Phase 2 Trial for Adrenocortical Carcinoma Through Cancer Research UK Collaboration
• Cytovation's CY-101, a synthetic peptide, will be evaluated in a Phase 2 trial for adrenocortical carcinoma (ACC) patients, a rare and aggressive cancer with limited treatment options.
• Cancer Research UK's Centre for Drug Development will manage the multi-national trial across the UK and Europe, while Cytovation will supply CY-101 for the study.
• CY-101 targets and destroys cancer cells, stimulates an immune response, and inhibits the Wnt/β-catenin pathway, potentially overcoming immunotherapy resistance in ACC.
• The Norwegian Cancer Society is co-funding the trial, supporting access to resources and patients, highlighting a commitment to advancing treatments for rare cancers.
© Copyright 2025. All Rights Reserved by MedPath